Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (299)	12/18/1997 12:30:00 AM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

From Ivax's 3/97 10K... PAXENE(trademark). Paxene(trademark), IVAX' tradename for paclitaxel, is an off-patent compound which, in clinical trials sponsored by the National Cancer Institute, exhibited promising results in the treatment of ovarian, breast and other cancers. Bristol-Myers Squibb Company currently markets a product containing paclitaxel under the brand name Taxol(R) for the treatment of ovarian and breast cancer, and under applicable law, the FDA will not accept an ANDA for a generic version of this product until December 1997. [Looks like immunex got the jump on Ivax here.] IVAX has entered into an exclusive agreement with NaPro BioTherapeutics, Inc. ("NaPro") to develop and market in the United States, Eurpoe and certain other territories paclitaxel supplied by NaPro. IVAX intends to submit an NDA for Paxene(trademark) for at least one indication during 1997. IVAX is also conducting research involving analogues of paclitaxel and novel delivery systems for this class of drugs. Is the NDA for generic Taxol going to happen? Is that precluded by Immunex's application? One more for IR tomorrow. Jackson